Project Grant R21CA290139
Award Date
6/17/24
Completion Date
5/31/26
Dollars Obligated
$379K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Baton Rouge, LA 70803, USA
Similar Awards
This $678,723 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Baylor College of Medicine to study the role of PD-L1 protein modifications in lung cancer diagnosis, prognosis, and treatment. The 5-year project, starting February 2025, aims to evaluate the clinical significance of PD-L1 and an associated E3 ligase enzyme in lung cancer, as well as dissect the molecular mechanisms of PD-L1 ubiquitination and its impact on...
This federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) provides $635,248 to Trustees of Boston University to develop a modified self-amplifying ribonucleic acid (SARNA) technology encoding for a bispecific T cell engaging (BiTE) antibody to treat lung cancer. The key product is the 5-methylcytidine (5MC) modified SARNA construct encoding the BiTE antibody, which aims to enhance protein expression, reduce innate immune...
The National Cancer Institute (NCI) awarded a $355,706 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Washington University in St. Louis to conduct research on understanding the role of the long non-coding RNA, RAMS11, in promoting non-small cell lung cancer (NSCLC). The research aims to determine how RAMS11 interacts with the NRF2 transcription factor to regulate cancer-specific gene expression programs, with the goal of identifying new biomarkers and targeted therapeutic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that leverages tumor-associated proteases to selectively deliver a potent cytotoxin into cancer cells. The goal is to create a targeted therapeutic strategy to improve treatment outcomes for metastatic and recurrent solid tumors, including ovarian, lung, and colon cancers. Key elements of the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $530,786 to The Leland Stanford Junior University to conduct research on modulating cysteine metabolism to induce cell death in small cell lung cancer (SCLC). The award period runs from August 1, 2024 to July 31, 2029. The key objectives of this research are to determine how distinct neuroendocrine cell states in SCLC dictate the choice between apoptosis and ferroptosis cell death...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $450,429 to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research aimed at identifying novel therapeutic strategies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in combination with immune checkpoint inhibitors (ICIs) to restrain the progression of non-small cell lung cancer (NSCLC). The research will investigate how the...
The federal Project Grant award R01CA297605, totaling $696,569, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The funding supports research at New York University (NYU) School of Medicine aimed at targeting the small glycoprotein Lipocalin 2 (LCN2) as a novel therapeutic approach for treating KRAS-driven non-small cell lung cancer (NSCLC). The research seeks to characterize the impact of LCN2 on the tumor microenvironment,...
The U.S. National Cancer Institute awarded a $627,833 Project Grant (CFDA 93.396 Cancer Biology Research) to The University of Texas Southwestern Medical Center to develop an informatics platform that integrates molecular and pathology data from various lung cancer preclinical models and patient tumors. The platform will enable comparative analyses to assess the fidelity of preclinical models in representing human lung cancer. Key objectives include: Harmonizing molecular profiling datasets from...
This $1,139,931 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate the therapeutic potential of the sphingolipid analog drug FTY720 and its functional mimetics for treating non-small cell lung cancer (NSCLC). The primary awardee, the Medical University of South Carolina, will define the mechanisms by which FTY720 induces necroptosis in NSCLC cells through direct targeting of the SET oncoprotein, resulting in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to the University of Southern California to develop a new monoclonal antibody-based therapeutic for the treatment of small cell lung cancer (SCLC). The key objectives are to: 1) Generate a mouse monoclonal antibody specifically targeting an abnormal post-translational modification (isoaspartylation) of the ELAVL4 protein, which is expressed on the surface of SCLC...